{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:34Z","timestamp":1753891894926,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Delayed PET\/CT imaging with <jats:sup>68<\/jats:sup>Ga-PSMA-11 is valuable in the detection of primary prostate (PCa) lesions and the differentiation of suspicious lesions. However, <jats:sup>18<\/jats:sup>F-FDG PET\/CT has been overlooked due to its low sensitivity to PCa during routine examination. This study aimed to compare the clinical impact of PSMA and FDG in delayed PET\/CT imaging in PCa diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between 2019 and 2024, 65 PCa patients who underwent early (1 h post-injection) and delayed (3 h p.i.) PSMA and FDG scans were retrospectively analyzed. The delayed scans were conducted to clarify unclear findings in early scans or to increase the tumor lesions uptake in negative early scans. All patients were asked to drink 1 L of water between early and delayed scans. The number of primary and metastatic lesions, sensitivity, specificity, diagnostic accuracy, lesions changes in SUV<jats:sub>max<\/jats:sub> of early and delayed scans were evaluated. Correlation between SUV<jats:sub>max<\/jats:sub> and Gleason score as well as SUV<jats:sub>max<\/jats:sub> and PSA for PCa primary lesions diagnosis were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 83 and 84 lesions characteristic for PCa in 65 patients clearly presented at 1 h and 3 h p.i. in PSMA scans, respectively. 30 and 45 lesions characteristic for PCa in 65 patients clearly presented at 1 h and 3 h p.i. in FDG scans. The 3-hour delayed imaging of FDG found more primary foci than 1-hour imaging but was much less able to detect metastatic foci than PSMA. PSMA was more sensitive than FDG in delayed imaging (96.15% vs. 84.21%), and the diagnostic accuracy for primary foci was higher for PSMA than FDG in delayed imaging (83.87% vs. 73.91%). However, FDG delayed imaging greatly improved the diagnostic accuracy for primary PCa compared to early imaging (73.91% vs.53.33%). PSMA SUV<jats:sub>max<\/jats:sub> of both 1 h and 3 h p.i. were correlated with the Gleason score PSA, but FDG SUV<jats:sub>max<\/jats:sub> only showed a correlation with PSA at 3 h p.i.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PSMA PET\/CT at 3 h p.i. detected the most lesions characteristic of primary PCa, and it showed higher uptake and contrast than FDG. However, to some extent, FDG delayed PET\/CT imaging is still important in primary PCa diagnosis, particularly in hospitals without PSMA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1515653","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:10:38Z","timestamp":1744344638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-head comparison of 68Ga-PSMA-11 and 18F-FDG in delayed PET\/CT imaging in prostate cancer diagnosis"],"prefix":"10.3389","volume":"15","author":[{"given":"Biyao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haonan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiling","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaobo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiusong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.11.008","article-title":"Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246363","article-title":"Diagnostic accuracy of (18)F-PSMA-1007 PET\/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence","volume":"62","author":"Sprute","year":"2021","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2020191689","article-title":"PSMA-targeted Radiotracers versus (18)F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis","volume":"296","author":"Tan","year":"2020","journal-title":"Radiology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J Nucl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183483","article-title":"The clinical impact of additional late PET\/CT imaging with (68)Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer","volume":"58","author":"Afshar-Oromieh","year":"2017","journal-title":"J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.12182\/20240960201","article-title":"Clinical value of dual tracer PET imaging with (68)Ga-PSMA and (18)F-FDG in patients with metastatic prostate cancer","volume":"55","author":"Dai","year":"2024","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267899","article-title":"(68)Ga]Ga-PSMA-11 PET and prostate cancer bone metastases: diagnostic performance of available standardized criteria","volume":"65","author":"Mainta","year":"2024","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267591","article-title":"Clinical factors that influence repeat (68)Ga-PSMA-11 PET\/CT scan positivity in patients with recurrent prostate cancer under observation after a negative (68)Ga-PSMA-11 PET\/CT scan: A single-center retrospective study","volume":"65","author":"Thin","year":"2024","journal-title":"J Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04967-9","article-title":"The value of (18)F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis","volume":"48","author":"Ayati","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","article-title":"Role of FDG PET\/CT in management of patients with prostate cancer","volume":"54","author":"Sutherland","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000002367","article-title":"Intertumoral heterogeneity of 18F-FDG and 68Ga-PSMA uptake in prostate cancer pulmonary metastases","volume":"44","author":"Perez","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000002013","article-title":"Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET\/CT and 68Ga-DOTANOC PET\/CT over 68Ga-PSMA PET\/CT","volume":"43","author":"Parida","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000032331","article-title":"Comparison of 18F-FDG PET\/CT imaging with different dual time 18F-FDG PET\/CT with forced diuresis in clinical diagnosis of prostate cancer","volume":"102","author":"Yu","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3670-z","article-title":"(68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1","volume":"44","author":"Fendler","year":"2017","journal-title":"0. Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180093","article-title":"Pitfalls of a mixed metabolic response at PET\/CT","volume":"39","author":"Clark","year":"2019","journal-title":"Radiographics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231068","article-title":"Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: A mechanistic perspective for (18)F-FDG imaging of PSMA-suppressed tumors","volume":"61","author":"Bakht","year":"2020","journal-title":"J Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/biom15010017","article-title":"Atypical metastases from prostate cancer: alpha-methylacyl-coenzyme A racemase (AMACR) as a potential molecular target in prostate-specific membrane antigen-negative prostate adenocarcinoma","volume":"15","author":"Badrane","year":"2024","journal-title":"Biomolecules"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-024-00235-3","article-title":"B-CLL with negative (18)F-FDG PET\/CT and intensive solitary lesion on PSMA PET\/CT mimicking prostate cancer bone metastases","volume":"9","author":"Jung","year":"2025","journal-title":"EJNMMI Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005518","article-title":"FDG PET\/CT scan still can help in evaluation of prostate cancer","volume":"50","author":"Doroudinia","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005587","article-title":"Dual-tracer 18 F-FDG and 68 ga-PSMA PET\/CT imaging of heterogeneous phenotypes of metastatic castration-resistant prostate cancer for predicting response to novel hormone therapy","volume":"50","author":"Bian","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005607","article-title":"Incidental detection of prostatic lesion on 18 F-FDG PET\/CT and 68 ga-PSMA-11 PET\/CT leading to diagnosis of second primary prostatic adenocarcinoma in a patient of differentiated thyroid cancer","volume":"50","author":"Gondhane","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0202-x","article-title":"GLUT1 expression in high-risk prostate cancer: correlation with (18)F-FDG-PET\/CT and clinical outcome","volume":"23","author":"Meziou","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/diagnostics12030581","article-title":"Beyond the prognostic value of 2-[(18)F]FDG PET\/CT in prostate cancer: A case series and literature review focusing on the diagnostic value and impact on patient management","volume":"12","author":"Borea","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s00259-013-2361-7","article-title":"Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET\/CT: utility and limitations","author":"Jadvar","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B34","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.euf.2018.03.008","article-title":"Increased prostate cancer glucose metabolism detected by (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in localised gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration","volume":"5","author":"Lavall\u00e9e","year":"2019","journal-title":"Eur Urol Focus"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1515653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:10:40Z","timestamp":1744344640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1515653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1515653"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1515653","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1515653"}}